Fenbendazole (Panacur, Safe-Guard) is an anthelmintic medication used to treat parasites. It destroys microtubules that cancer cells need to grow, and prevents them from processing sugar which they use for energy. It also boosts the production of a gene called p53, which cancer patients sometimes lack.
A patient with stage 4 kidney cancer began taking fenbendazole on her own in addition to her standard medical care and later experienced severe liver injury. The patient reported that she had received information about the antitumor activity of fenbendazole via social media, purchased the drug, and orally self-administered it.
We investigated the effect of fenbendazole on the radiosensitivity of EMT6 tumors in BALB/cRw mice and found that it had no significant effects alone or in combination with radiation. Similarly, we found no difference in the growth of unirradiated or irradiated tumors, which were analyzed by comparing the time to the next peak of volume in each group.
The benzimidazole compounds, including fenbendazole, have long been used as antiparasitic agents and are thought to act by disrupting the tubulin microtubule equilibrium in lower organisms by binding to and inhibiting polymerization of microtubules. Although fenbendazole is toxic to helminths, its broad antiparasitic spectrum and relatively low absorption in mammalian tissues permit it to have a number of other biological actions, including cytotoxic activity against human carcinoma cell lines and p53-related gene expression in lung cancer cells with a KRAS mutation (7). These results provide no evidence that fenbendazole has value as an anticancer agent, but the general class of benzimidazole compounds merits further investigation as potential anticancer drugs. fenbendazole stage 4 cancer